Synagis®: Terms and Conditions

MedImmune provides the materials on this website for general informational, educational, and disease awareness purposes. Although accessible by others, the website and its content are intended strictly for access and use by U.S. residents only.

Please carefully read these Terms and Conditions that apply to your access and to the use of the website. By accessing or using the website, you agree to be bound by these Terms and Conditions. If you do not agree to be bound by these Terms and Conditions, please discontinue access and use of the website. We reserve the right to revise these Terms and Conditions or any portion of them at any time and in any way without notice by updating this posting. Your use of this website is subject to any such revisions and you should periodically visit this page to review the current Terms and Conditions that apply to your use of this website.

The website contains information concerning respiratory syncytial virus (RSV) and Synagis® (palivizumab) that may be useful to our customers, patients, investors, employees and shareholders as well as the general public. MedImmune makes no representations or warranties and assumes no responsibility or liability as to the accuracy, completeness, reliability or usefulness of any information contained on the website. Further, MedImmune expressly disclaims any obligation to update or correct information contained on the website and explicitly disclaims any duty to do so. MedImmune assumes no liability or responsibility for any errors or omissions in the content of the website. MedImmune reserves the right to make additions, deletions or modifications to the information or materials on the website at any time and in any way without notice.

The information presented on this website is not intended to provide medical advice or to provide instructions on the use of our products, and should not be relied upon as the basis of any health-care decision. This information is not intended to replace informed medical advice from your qualified health-care provider regarding any questions or concerns you may have about your health or about the potential beneficial uses and possible adverse effects of any health-care product.

The statements in this website that are not descriptions of historical facts may be forward-looking statements. Those statements involve substantial risk and uncertainties. You can identify those statements by the fact that they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "project" or other terms of similar meaning. These statements reflect beliefs of management that were current at the time they were made and were based on numerous assumptions which MedImmune cannot control and which may not develop as MedImmune expects. Consequently, actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially are: Seasonal demand for and continued supply of our principal product; availability of competitive products in the market; availability of third-party reimbursement for the cost of our products; effectiveness and safety of our products; exposure to product liability, intellectual property or other types of litigation; foreign currency exchange rate fluctuations; changes in generally accepted accounting principles; growth in costs and expenses; the impact of acquisitions, divestitures and other unusual items; and the risks, uncertainties and other matters discussed elsewhere in this website and in our periodic reports filed with the U.S. Securities and Exchange Commission. MedImmune cautions that RSV season usually starts in the fall and continues into spring: MedImmune believes its operating results will reflect that seasonality for the foreseeable future. MedImmune is also developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

All content of the MedImmune website is protected to the fullest extent possible by copyright laws. You may not copy, modify, upload, download, post, transmit, republish or distribute any of the content, including without limitation the HTML or other software instructional code, contained in our website without our prior written permission except for your own personal, non-commercial purposes. Nothing contained in this website shall be construed as granting a license or other rights under any patent, trademark, copyright or other intellectual property of MedImmune or any third party. Please be advised that MedImmune actively enforces its intellectual property rights to the fullest extent allowed by applicable laws.

Nothing on this website constitutes or is intended to constitute an invitation or offer to invest or deal in the securities of MedImmune.

Synagis® is a registered trademark of MedImmune, Inc. All other registered trademarks and trademarks are property of their respective owners.

We have provided links to certain other third party websites merely as a convenience for users of the Synagis.com website. These websites are maintained on third party servers and are not under the control of MedImmune. We do not control the material on such third party websites. Access to such third party websites is at the user's own risk and MedImmune is not responsible for its accuracy or reliability. Inclusion of such links to third party websites does not constitute an endorsement, approval, or guarantee the accuracy of the contents of any linked websites, including any of the opinions and predictions of any financial analysts with respect to MedImmune or any of its securities. We expressly disclaim any responsibility for the content of any third party websites linked to our website. We urge you to use discretion when you access any third party websites linked to our website.

The content on the synagis.com website is provided "as is" and MedImmune makes no representations or warranties of any kind, whether express or implied, created by law, contract or otherwise, including, but not limited to, any warranties of merchantability, fitness for a particular purpose, title or non-infringement. MedImmune makes no representation or warranty that access to the website will be available on a continuous basis, will be uninterrupted, or that the information contained on the website will be timely, complete or error free.

Each person assumes full responsibility and all risks arising from access and use of the website. In no event shall any of MedImmune, our subsidiaries and their respective officers, directors, employees, agents, representatives, business partners, information providers and licensors and their respective heirs and assigns be liable for any damages of any kind or nature, including, but not limited to, direct, indirect, incidental, consequential, exemplary, special (including loss of profit), punitive or other damages arising from or in connection with the existence, access or use of the website, regardless of whether MedImmune or any of the other entities or persons listed above has been advised as to the possibility of such damages.

We do not warrant that the functions or informational materials contained in or accessed through out website are free of computer viruses or other harmful components. Although we make a good faith effort to update the content of our website periodically, we do not have a duty to update information contained in our website, and we will not be liable for any failure to update such information.

MedImmune assumes no responsibility or liability arising from the content of the website nor for any error, defamation, libel, slander, omission, falsehood, obscenity, pornography, profanity, danger or inaccuracy contained in any information within the website or accessed through the website.

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.